Asarina Pharma AB (STU:APS) Pre-Tax Income : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Asarina Pharma AB's pretax income for the three months ended in Dec. 2023 was €0.00 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil. Asarina Pharma AB's pretax margin was %.

Asarina Pharma AB Pre-Tax Income Historical Data

The historical data trend for Asarina Pharma AB's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Pre-Tax Income Chart

Asarina Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-7.53

-8.16

-3.73

-1.35

-1.30

Asarina Pharma AB Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-0.39	-0.39	-	-	-

Competitive Comparison of Asarina Pharma AB's Pre-Tax Income

For the Biotechnology subindustry, Asarina Pharma AB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asarina Pharma AB's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asarina Pharma AB's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Asarina Pharma AB's Pre-Tax Income falls into.

Asarina Pharma AB Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Asarina Pharma AB's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.309	+	0	+	-0.005	+	0.011	+	0
	=	-1.30

Asarina Pharma AB's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	0	+	0	+	0	+	0	+	0
	=	0.00

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Asarina Pharma AB (STU:APS) Pre-Tax Income Explanation

Asarina Pharma AB's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	0	/	0
	=	%

Asarina Pharma AB Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Asarina Pharma AB (STU:APS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (STU:APS) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

ASAP:Sweden

Address

Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65

Website

https://www.asarinapharma.com

Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (STU:APS) Headlines

No Headlines